Tesamorelin vs MOTS-c
Both compounds have been studied for their effects on metabolic parameters, but through entirely different signalling axes. Tesamorelin is a synthetic GHRH analogue that stimulates pulsatile growth-hormone release via the pituitary GHRH receptor. MOTS-c is a mitochondrial-derived peptide that activates the AMPK pathway. This page summarises how the published research separates their mechanistic profiles and evidence bases.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | Modified GHRH(1-44) analogue with N-terminal hexenoic acid modification | 16-residue peptide encoded within the mitochondrial 12S rRNA gene |
| Receptor/pathway target | GHRH receptor on pituitary somatotrophs; pulsatile GH/IGF-I axis | AMPK pathway activation; nuclear translocation under metabolic stress |
| Clinical evidence base | FDA approved for HIV-associated lipodystrophy; multiple Phase 3 RCTs | Preclinical rodent models; no large-scale clinical trials |
| Primary research endpoints | Visceral fat reduction, liver enzymes, inflammatory markers, neurocognitive outcomes | Metabolic homeostasis, insulin sensitivity, exercise physiology, age-related metabolic decline |
| Origin | Synthetic analogue of endogenous GHRH | Endogenous mitochondrial-derived peptide |
| Common research administration route | Subcutaneous injection | Subcutaneous or intraperitoneal injection in rodent studies |
| Ronin catalog vial size | 10 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
Tesamorelin engages the GHRH receptor on pituitary somatotrophs to stimulate pulsatile growth-hormone release. Downstream, GH drives IGF-I secretion from the liver and modulates adipose-tissue metabolism. The clinical literature documents visceral-fat reduction in HIV-associated lipodystrophy, improvements in liver enzymes and inflammatory markers, and effects on hepatic transcriptomic signatures. The mechanism is well characterised and clinically validated through Phase 3 randomised controlled trials.
MOTS-c is encoded within the mitochondrial genome and acts through the AMPK (AMP-activated protein kinase) pathway. Under metabolic stress, the published mechanistic work describes nuclear translocation of MOTS-c and regulation of the nuclear transcriptome. Functional endpoints in rodent models include metabolic homeostasis, improved insulin sensitivity, and enhanced exercise capacity. The peptide’s mitochondrial origin positions it as part of the broader mitochondrial-derived-peptide signalling field.
The two compounds operate on entirely different signalling axes. Tesamorelin works through the hypothalamic-pituitary GH/IGF-I axis. MOTS-c works through mitochondrial-nuclear retrograde signalling and AMPK activation. They share the broad theme of metabolic modulation but have no mechanistic intersection in the published literature.
How research has examined each
The tesamorelin literature includes Phase 3 trials by Falutz and colleagues in HIV-associated lipodystrophy, metabolic-outcome studies by Stanley and Fourman, and hepatic-transcriptomic work. The compound has FDA approval for the HIV-lipodystrophy indication, positioning it as one of the most clinically validated GHRH analogues. More recent work has examined neurocognitive endpoints in persons with HIV.
The MOTS-c literature has expanded since the 2015 characterisation by Lee et al. Published work spans metabolic homeostasis, gestational diabetes, exercise physiology, neuropathic pain, cardiovascular endpoints, radiation pneumonitis, and cancer-biology contexts. The peptide’s endogenous mitochondrial origin and its activity across multiple organ systems have attracted broad research interest, though the literature remains at the preclinical stage.
The evidence-base asymmetry is the defining comparison point. Tesamorelin has Phase 3 RCT data with FDA approval. MOTS-c has expanding preclinical data without human clinical trials. Researchers positioning the two in a metabolic-research context note the clinical validation gap and the non-overlapping signalling pathways.
Stacking considerations in research contexts
Combined administration of tesamorelin and MOTS-c is not described in the published literature. The signalling axes do not overlap (GHRH-receptor-mediated GH release versus AMPK-mediated metabolic signalling), so no direct pharmacological collision is anticipated, but no published protocol describes the combination. Both compounds are sold as separate 10 mg lyophilised vials in the Ronin catalog.
Sourcing both at Ronin
Both compounds in the Ronin catalog ship as 10 mg lyophilised peptide in glass vials, capped and crimped, with certificate-of-analysis documentation (mass spec + HPLC purity) on the lab-results page. The tesamorelin vial page and the MOTS-c vial page carry per-compound spec sheets, reconstitution math, and storage guidance. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.
Frequently asked research questions
Do these compounds target the same pathway?
No. Tesamorelin engages the GHRH receptor to stimulate pulsatile GH release via the hypothalamic-pituitary axis. MOTS-c activates the AMPK pathway through mitochondrial-nuclear retrograde signalling. The pathways are unrelated.
Which has more clinical evidence?
Tesamorelin has Phase 3 randomised controlled trials and FDA approval for HIV-associated lipodystrophy. MOTS-c has preclinical data across multiple model systems but no large-scale clinical trials.
Is MOTS-c endogenous?
Yes. MOTS-c is encoded within the mitochondrial genome (12S rRNA gene) and has been detected endogenously. Tesamorelin is a synthetic analogue of the endogenous hormone GHRH.
Do they share storage practice?
Yes. Both are lyophilised peptides in glass vials, reconstituted in bacteriostatic water, and stored refrigerated at 2-8 °C protected from light.
Are either approved for human use under the Ronin brand?
No. Tesamorelin is FDA-approved under a separate brand name. MOTS-c is not approved as a therapeutic. Both Ronin vials are research-grade reagents for laboratory use only.
References
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. [PMID 18057338]
- Falutz J et al. Effects of tesamorelin on visceral fat in HIV with abdominal fat accumulation. Journal of Acquired Immune Deficiency Syndromes, 2010. [PMID 20101189]
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. [PMID 25738459]
- Kim KH et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression. Cell Metabolism, 2018. [PMID 29983246]
- Fourman LT et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 2020. [PMID 32701508]
- Wan W et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine, 2023. [PMID 36670507]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.